|
May 15
|
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...
|
|
May 15
|
Q1 2025 PDS Biotechnology Corp Earnings Call
|
|
May 14
|
PDS Biotechnology: Q1 Earnings Snapshot
|
|
May 14
|
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
|
|
Apr 16
|
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
|
|
Jul 29
|
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
|
|
May 15
|
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
Jan 16
|
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
|
|
Dec 4
|
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 28
|
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
|
|
Sep 6
|
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Sep 6
|
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
|
|
Aug 16
|
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
|
|
Jul 17
|
PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023
|